Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 19;11(6):e4943.
doi: 10.7759/cureus.4943.

Fractional Laser-assisted Hair Regrowth and Microneedling for the Treatment of Alopecia Areata: A Review

Affiliations
Review

Fractional Laser-assisted Hair Regrowth and Microneedling for the Treatment of Alopecia Areata: A Review

Robert J Dabek et al. Cureus. .

Abstract

Alopecia areata (AA) affects approximately 2.1% of the population, with women being affected more often than men. Current therapies consisting of topical corticosteroids or intralesional injections are often the first choices for treatment, but are limited by unsatisfactory outcomes or risks to patients. Recently, fractional lasers and microneedling, with or without the addition of topical agents, have been examined as treatment options. A literature review was performed to evaluate the efficacy of fractional lasers in the treatment of AA. A total of six fractional lasers and two microneedling studies consisting of small prospective and retrospective studies, and case reports were reviewed. The number of trials and participants are limited, but evidence suggests that fractional lasers and microneedling may be effective therapeutic approaches when coupled with topical agents. Larger studies are required to better understand the effects of these treatment modalities for AA.

Keywords: alopecia areata; fractional lasers; hair loss; laser-assisted drug delivery; lasers; microneedling.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Similar articles

Cited by

References

    1. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009. Mirzoyev SA, Schrum AG, Davis MDP, Torgerson RR. J Invest Dermatol. 2014;134:1141–1142. - PMC - PubMed
    1. Guidelines for the management of alopecia areata. Hull SPM, Wood ML, Hutchinson PE, Sladden M, Messenger AG. Br J Dermatol. 2003;149:692–699. - PubMed
    1. Review of quality of life studies in women with alopecia. Davis DS, Callender VD. Int J Womens Dermatol. 2018;4:18–22. - PMC - PubMed
    1. Alopecia areata: a review of disease pathogenesis. Rajabi F, Drake LA, Senna MM, Rezaei N. Br J Dermatol. 2018;179:1033–1048. - PubMed
    1. Histopathology of alopecia: a clinicopathological approach to diagnosis. Stefanato CM. Histopathology. 2010;56:24–38. - PubMed

LinkOut - more resources